Form 4 for KYNB KYNTRA BIO, INC.
Accepted 2021-10-06 00:00:00 ET · period of report 2021-10-04 · accession 0001209191-21-059869 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2021-10-06 | 2021-10-04 | KYNB | Eisner Mark | Chief Medical Off | A - Grant | $0.00 | +74.5K | 109.5K | +213% | $0 |
| D | 2021-10-06 | 2021-10-04 | KYNB | Eisner Mark | Chief Medical Off | A - Grant | $0.00 | +44.5K | 44.5K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2021-10-04 | A | A | 74,520 | $0.00 | 109,520 | D | — | — | (F1) Represents the grant of restricted stock units. Twenty-five percent of the restricted stock units vest on each December 31, 2021, March 31, 2022, September 30, 2022 and March 31, 2023. |
| 2 | Derivative | Stock Option (Right to Buy) | 2021-10-04 | A | A | 44,520 | $0.00 | 44,520 | D | $9.93 · — to 2031-10-04 | 44,520 Common Stock | (F2) Fifty percent of the shares subject to the option vests on each September 30, 2022 and March 31, 2023. |